Biotech Values

[oc631]

They do have a slightly later-stage pre-clinical nucleotide partnered with Janssen that is set to enter the clinic this year

My understanding is they are working on purine and pyrimidine nucleotides. Any idea which one is partnered?

I'm not 100% certain but I think they will be testing in additional genotypes in this trial; prior trials have only tested in genotype 1. If anyone listens to the CC, please clarify if this is your understanding as well.)

I'm not sure about the trial design [TMC435] but they claim sufficient activity in all genotypes except GT3.

I think you will do well with this company once battle lines between developers are drawn this year.